000950 重药控股
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.1863.3832.5115.7139.303
总资产报酬率 ROA (%)0.3790.5820.4351.0351.782
投入资产回报率 ROIC (%)0.6190.9660.7381.7102.795

边际利润分析
销售毛利率 (%)6.7917.2057.4347.9938.581
营业利润率 (%)1.0190.8280.6981.2312.116
息税前利润/营业总收入 (%)1.8471.7102.0382.8933.784
净利润/营业总收入 (%)0.7790.6320.4990.9321.715

收益指标分析
经营活动净收益/利润总额(%)148.482169.722129.526108.17482.894
价值变动净收益/利润总额(%)33.12061.38473.42232.87820.079
营业外收支净额/利润总额(%)2.229-1.639-0.9210.1502.545

偿债能力分析
流动比率 (X)1.1861.2181.3031.2721.198
速动比率 (X)0.9851.0041.0771.0721.004
资产负债率 (%)75.45175.00875.29175.63877.776
带息债务/全部投入资本 (%)71.08069.72969.68966.94969.010
股东权益/带息债务 (%)38.94841.54440.36146.04442.106
股东权益/负债合计 (%)22.85523.21922.57923.35823.946
利息保障倍数 (X)2.2941.9101.5141.7422.346

营运能力分析
应收账款周转天数 (天)169.464150.646145.517139.277144.535
存货周转天数 (天)48.15447.09744.84841.08940.388